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Abstract
Background: In the last years significant attention has been paid in identifying markers of subclinical
atherosclerosis or of increased cardiovascular risk.
Method: An abnormal ankle/brachial index (ABI) identifies patients affected by lower extremity peripheral arterial
disease, and even more important, represents a powerful predictor of the development of future ischemic
cardiovascular events.
Conclusions: In our opinion, ABI is a cardiovascular risk prediction tool with very desirable properties that might
become a routine measurement in clinical practice.
Cardiovascular diseases are the leading causes of morbid-
ity and mortality in the western world [1-4], and athero-
sclerosis is the underlying cause of the majority of
cardiovascular diseases [5,6]. Lower extremity peripheral
arterial disease (LE-PAD) is one of the main manifesta-
tions of atherosclerosis affecting about 20% of the popu-
lation aged 55 and older [7,8]. It has been calculated that
about 27 millions people in Europe and United States
suffer from this pathology [9], thus representing a socio-
economic problem of great magnitude [10]. In particular,
elderly populations have more severe forms of athero-
sclerosis with a higher prevalence of polidistrectual dis-
ease including carotid arteries and abdominal aorta
[11-13] and develop a higher grade of disability compared
with younger people [14]. In addition to be an important
cause of disability in its symptomatic forms (intermittent
claudication and critical limb ischemia), LE-PAD is asso-
ciated with an elevated risk of developing ischemic cardio-
vascular events [3,6,15-17], which is similar in symptomatic
and asymptomatic patients [16-20].
LE-PAD diagnosis can be made simply, accurately and
non-invasively by ankle/brachial index (ABI) measurement
[8,18,21]. The assessment involves placing a sphygmoman-
ometer cuff just above the ankle and using a Doppler
instrument to measure the systolic pressure of the poster-
ior tibial and dorsalis pedis arteries of each leg. The ABI is
then obtained dividing the systolic pressure of each of the
ankles by the highest brachial pressure of either arm [21].
A patient’s ABI is defined as the lowest of the leg ABI
measurements (Figure 1). A resting ABI value ≤0.90
defines the presence of LE-PAD and it has a sensibility of
about 95% in identifying the presence of a hemodynami-
cally significant arterial stenosis at angiography between
heart and foot and near 100% specificity in excluding a
normal subject [18]. Furthermore, ABI gives important
information about LE-PAD severity, which is higher with
a lower ABI value. In addition to its diagnostic utility, an
abnormal ABI value represents a powerful predictor of the
development of future ischemic cardiovascular events
[3,18,21,22]. Such risk increases with the decrement of the
ABI value and it is independent of the presence or absence
of the classic cardiovascular risk factors [22]. In this
regard, it is important to note that although classic cardio-
vascular risk factors are useful to predict risk in popula-
tions, their accuracy in predicting cardiovascular risk in
individuals varies considerably. Indeed, in the last years
significant attention has been paid in identifying markers
of subclinical atherosclerosis or of increased cardiovascular
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risk in humans as well as animal models [23-27]. Although
several tools have been proposed [27-29], frequently the
clinical utility of measuring such markers remains uncer-
tain for several reasons, including costs, low reproducibil-
ity, conflicting studies or lack of confirmatory studies, and
lack of measurement standardization [27]. Additional
research will be needed to quantify the impact and cost
effectiveness of these markers on patient management and
clinical outcomes, with simplicity of assessment and low
cost being the essential characteristics of an optimal risk
marker.
Given that the vast majority of LE-PAD patients is
asymptomatic and that an abnormal ABI has an impor-
tant power in predicting the occurrence of future cardiac
and cerebrovascular ischemic events, it would be extre-
mely important to identify which populations need to be
screened with this inexpensive tool. Several epidemiolo-
gic studies, including the PARTNERS [8], and the latest
guidelines [18,21] suggest that subjects who should
undergo to ABI measurement are:
• All subjects who have exertion leg symptoms (also
atypical) or not healing wounds;
• All subjects of 50 years and older with a history of
smoking or diabetes;
• All subjects with age >65 years independent from
the presence of cardiovascular risk factors.
Although such recommendations are already quite
extensive, in our opinion they could be even broadened,
given the non-invasive nature, the low cost and the ele-
vated sensibility and specificity of ABI. In particular, all
patients with coronary artery disease (CAD) should be
screened, since in this population the presence of LE-PAD
is relatively frequent (16-20%), entails a higher severity of
the coronary disease [30,31], and is associated with a
worse prognosis [32]. Given the multidistrectual nature of
atherosclerosis, also patients affected by cerebrovascular
disease should undergo ABI measurement to identify, like
in CAD, a subgroup at even higher risk that should receive
higher clinical consideration.
Noteworthy, ABI has the power to provide additional
risk stratification of those subjects who have a 10-year
intermediate cardiovascular risk (between 10 and 20%)
[21,33]. In these individuals, the finding of an abnormal
ABI value switches the patients towards a higher cardio-
vascular risk which needs secondary prevention, while a
normal ABI could lower the risk estimation to the need of
primary prevention. Identification of individuals with
asymptomatic lower extremity PAD is of utmost impor-
tance, so that therapeutic interventions known to diminish
their increased risk of myocardial infarction, stroke, and
death may be offered [3]. Smoking cessation, lipid lower-
ing, diabetes and hypertension treatment and antiplatelet
Figure 1 How to perform ankle/brachial index.
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therapy are recommended to reduce the risk of adverse
cardiovascular ischemic events [34]. In this context, it
should be acknowledged that statins are particularly effec-
tive in reducing cardiovascular risk of patients with
LE-PAD, even if with normal cholesterol levels [35]. In
conclusion, because of the simplicity of execution and for
the diagnostic and prognostic importance, ABI, in our opi-
nion, might become a routine measurement in clinical
practice, also in the general practitioner setting. Indeed,
early identification of subclinical atherosclerosis and
LE-PAD might offer a unique opportunity to put on time
into effect the necessary prevention measures.
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